https://scholars.lib.ntu.edu.tw/handle/123456789/473832
標題: | Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers | 作者: | YIH-LEONG CHANG CHEN-TU WU JIN-YUAN SHIH Lee Y.-C. |
公開日期: | 2011 | 卷: | 18 | 期: | 2 | 起(迄)頁: | 543-550 | 來源出版物: | Annals of Surgical Oncology | 摘要: | Background: To obtain insight into the cancer progression and metastatic process, we evaluate p53/epidermal growth factor receptor (EGFR) somatic aberrations in non-small-cell lung cancers to compare accumulated genetic alterations between primary tumors and lymph node metastases. Materials and Methods: A total of 56 primary lung cancers with corresponding lymph node metastases were identified to investigate somatic mutations and altered expressions of p53 and EGFR for clonality assessment. Genomic DNA was extracted from macrodissected cells of paraffin-embedded primary tumor and metastatic lymph node tissues. Overexpression and somatic mutations in exons of p53 (exons 5-8) and tyrosine kinase domain of EGFR (exons 18-21) were examined by immunohistochemical staining and DNA sequencing, respectively. Results: p53 and EGFR mutation/overexpression status were different between primary tumors and lymph node metastases in 5.4/7.2% and 28.6/33.9%, respectively. In most cases, the p53 and EGFR mutations usually preceded lymph node metastasis, and these gene statuses in the primary cancer and their lymph node metastasis were concordant (92.9 and 69.6%, respectively), which further supported the hypothesis that when these p53 mutations occur before the establishment of lymph node metastasis, they subsequently persist in the metastatic nodes. The expressions of p53 and EGFR showed 7.1 and 33.9% discordance in that order. Conclusions: Our results reveal that p53 and EGFR mutations usually precede lymph node metastasis. The higher prevalence of EGFR heterogeneity existing in the primary tumor is not reflected in all lymph node metastasis and thus might have therapeutic implications when adjuvant therapy is considered. ? 2010 Society of Surgical Oncology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951553839&doi=10.1245%2fs10434-010-1295-6&partnerID=40&md5=73a74414a0bb8d99d40163a5a607ee0f https://scholars.lib.ntu.edu.tw/handle/123456789/473832 |
ISSN: | 1068-9265 | DOI: | 10.1245/s10434-010-1295-6 | SDG/關鍵字: | epidermal growth factor receptor; genomic DNA; paraffin; protein p53; protein tyrosine kinase; adult; aged; article; cancer growth; clinical article; clonal variation; comparative study; controlled study; DNA sequence; female; gene overexpression; human; immunohistochemistry; lung non small cell cancer; lymph node metastasis; male; mutation; primary tumor; protein expression; somatic mutation; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Exons; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Receptor, Epidermal Growth Factor; Tumor Suppressor Protein p53 |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。